<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="138026">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02118181</url>
  </required_header>
  <id_info>
    <org_study_id>Not Avalaible</org_study_id>
    <nct_id>NCT02118181</nct_id>
  </id_info>
  <brief_title>Assessment of Physical Performance With A Supplementation Containing HMB in a Sample of Old Women in Good Health</brief_title>
  <acronym>HMB</acronym>
  <official_title>Role of Oral Supplementation of Proteins and β-hydroxy-β-methyl Butyrate (HMB) in a Sample of Older Women in Good Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Padova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Padova</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a supplementation containing
      β-Hydroxy-β-methylbutyrate is effective in the treatment of age-related muscle loss in a
      group of older women compared to a non interventional group
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Short Physical Performance Battery</measure>
    <time_frame>Baseline and after 2 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Age Related Muscle Loss</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HMB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group taking oral supplementation with Beta-hydroxy-beta-methylbutyrate</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>HMB</intervention_name>
    <arm_group_label>HMB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  People over 65 years, not residents in nursing home, in good health

          -  Mini Mental State Examination (corrected for scholarity) more than 23

        Exclusion Criteria:

          -  Previous oral supplementation with proteins or minerals

          -  important co-mordidities, such renal or hepatic failure
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Sergi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Padova</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Padova</name>
      <address>
        <city>Padua</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Sergi, MD</last_name>
      <phone>00390498218492</phone>
      <email>giuseppe.sergi@unipd.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Sergi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 17, 2014</lastchanged_date>
  <firstreceived_date>April 16, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Padova</investigator_affiliation>
    <investigator_full_name>Giuseppe Sergi</investigator_full_name>
    <investigator_title>Dr, PhD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
